- Home
- WIA vs MCRB Comparison
WIA vs MCRB Comparison
Compare WIA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- MCRB
- Stock Information
- Founded
- WIA 2003
- MCRB 2010
- Country
- WIA United States
- MCRB United States
- Employees
- WIA N/A
- MCRB N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- MCRB Health Care
- Exchange
- WIA Nasdaq
- MCRB Nasdaq
- Market Cap
- WIA 196.4M
- MCRB 165.3M
- IPO Year
- WIA N/A
- MCRB 2015
- Fundamental
- Price
- WIA $8.43
- MCRB $17.95
- Analyst Decision
- WIA
- MCRB Hold
- Analyst Count
- WIA 0
- MCRB 4
- Target Price
- WIA N/A
- MCRB $73.67
- AVG Volume (30 Days)
- WIA 39.2K
- MCRB 247.1K
- Earning Date
- WIA 01-01-0001
- MCRB 11-12-2025
- Dividend Yield
- WIA 12.29%
- MCRB N/A
- EPS Growth
- WIA N/A
- MCRB N/A
- EPS
- WIA N/A
- MCRB 10.22
- Revenue
- WIA N/A
- MCRB N/A
- Revenue This Year
- WIA N/A
- MCRB N/A
- Revenue Next Year
- WIA N/A
- MCRB N/A
- P/E Ratio
- WIA N/A
- MCRB $1.71
- Revenue Growth
- WIA N/A
- MCRB N/A
- 52 Week Low
- WIA $7.56
- MCRB $6.53
- 52 Week High
- WIA $8.91
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- WIA 55.00
- MCRB 52.22
- Support Level
- WIA $8.40
- MCRB $14.22
- Resistance Level
- WIA $8.49
- MCRB $17.99
- Average True Range (ATR)
- WIA 0.06
- MCRB 2.05
- MACD
- WIA -0.00
- MCRB -0.39
- Stochastic Oscillator
- WIA 72.00
- MCRB 35.62
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.